HUTCHMED (China) Ltd

HCM Nasdaq SEC CIK 1648257
Follow HUTCHMED (China) Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 USD · US GAAP
EPS, diluted -

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income13 fiscal years
  • Revenue
  • Net income
−$500M$0$500M$1BFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$548.5M$456.9M
FY24$630.2M$37.7M
FY23$838M$100.8M
FY22$426.4M−$360.8M
FY21$356.1M−$194.6M
FY20$228M−$125.7M
FY19$204.9M−$106M
FY18$214.1M−$74.8M
FY17$241.2M−$26.7M
FY16$216.1M$11.7M
FY15$178.2M-
FY14$87.3M−$7.3M
FY13--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−100%−50%0%50%100%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2538.7%−7.1%83.3%
FY2444.6%−6.9%6%
FY2354.1%2.2%12%
FY2227%−95.6%−84.6%
FY21-−92.2%−54.7%
FY20-−86.3%−55.2%
FY19-−71.4%−51.7%
FY18-−43.3%−34.9%
FY1729.6%−22.1%−11.1%
FY1631%−21.6%5.4%
FY1541.2%−5.5%-
FY1438.8%−20.9%−8.4%
FY13---
Free cash flowOperating cash flow minus capital expenditure
−$400M−$200M$0$200MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$78.8M
FY24−$17.4M
FY23$186.6M
FY22−$305.3M
FY21−$220.6M
FY20−$70M
FY19−$89.5M
FY18−$39.2M
FY17−$14M
FY16−$13.9M
FY15−$12.7M
FY14$4.6M
FY13-
Returned to shareholdersDividends paid and shares bought back
$0$20M$40M$60MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25-
FY24$36.1M
FY23$9.1M
FY22$48.1M
FY21$27.3M
FY20$12.9M
FY19$346K
FY18$5.5M
FY17$1.4M
FY16$604K
FY15$1.8M
FY14-
FY13-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • HUTCHMED (China)
  • Healthcare median
−100%−50%0%50%100%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearHUTCHMED (China)Healthcare median
FY2583.3%−30.6%
FY246%−47%
FY2312%−58%
FY22−84.6%−80.4%
FY21−54.7%−71.9%
FY20−55.2%−62.2%
FY19−51.7%−46.3%
FY18−34.9%−49.6%
FY17−11.1%−45.9%
FY165.4%−36%
FY15-−38.4%
FY14−8.4%−35.5%
FY13-−37.1%